Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Naurex Inc.
Headquarters: Evanston, IL, United States of America
Website: N/A
Year Founded: 1994
Status: Acquired
BioCentury | Aug 23, 2022
Regulation
Aug. 23 Quick Takes: Clinical hold sinks Foghorn
Plus Third Harmonic consider IPO, eTheRNA raises €39M and updates from Gate, Freedom and more
BioCentury | Dec 22, 2017
Finance
Modulating mechanism
Why investors backed neurology company Aptinyx’s $70M series B
BioCentury | Jun 27, 2016
Emerging Company Profile
Next-gen NMDA
Why Aptinyx aims to modulate rather than block NMDA receptor activity
BioCentury | May 16, 2016
Finance
Naurex's New Leaf
Why New Leaf led a $65M A round for Naurex spinout Aptinyx
Items per page:
1 - 10 of 41